Cutera (CUTR) Upgraded at Zacks Investment Research

Zacks Investment Research upgraded shares of Cutera (NASDAQ:CUTR) from a sell rating to a hold rating in a report published on Tuesday.

According to Zacks, “Cutera Inc designs, develops, manufactures and markets the CoolGlide family of products for use in laser and other light-based aesthetic applications. The original CoolGlide CV provides permanent hair reduction on all skin types. The second generation CoolGlide Excel incorporated features that added the capability to treat a variety of vascular lesions, which include facial telangiectasia, spider and reticular leg veins. The CoolGlide Vantage added non-ablative skin therapy to the range of applications offered by the system. “

A number of other analysts also recently commented on the stock. BidaskClub upgraded shares of Cutera from a hold rating to a buy rating in a research report on Tuesday, December 12th. Maxim Group reaffirmed a hold rating on shares of Cutera in a research note on Wednesday, November 8th. Finally, Roth Capital lifted their price objective on shares of Cutera from $41.00 to $47.00 and gave the stock a buy rating in a research note on Tuesday, September 12th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The stock has a consensus rating of Buy and a consensus target price of $37.33.

Cutera (NASDAQ CUTR) traded up $2.95 during mid-day trading on Tuesday, hitting $49.35. 401,800 shares of the company’s stock were exchanged, compared to its average volume of 211,387. Cutera has a one year low of $18.00 and a one year high of $49.45. The company has a market cap of $697.10, a P/E ratio of 65.80, a price-to-earnings-growth ratio of 1.32 and a beta of 0.52.

Cutera (NASDAQ:CUTR) last released its quarterly earnings results on Tuesday, November 7th. The medical device company reported $0.42 EPS for the quarter, topping analysts’ consensus estimates of $0.08 by $0.34. Cutera had a net margin of 7.99% and a return on equity of 18.73%. The company had revenue of $38.17 million for the quarter, compared to the consensus estimate of $34.82 million. During the same period in the previous year, the firm earned $0.12 EPS. Cutera’s revenue was up 26.1% on a year-over-year basis. sell-side analysts predict that Cutera will post 0.55 EPS for the current fiscal year.

In other news, Director David B. Apfelberg sold 1,000 shares of Cutera stock in a transaction that occurred on Wednesday, October 18th. The shares were sold at an average price of $39.90, for a total value of $39,900.00. Following the transaction, the director now directly owns 10,259 shares of the company’s stock, valued at $409,334.10. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Timothy J. Oshea sold 4,000 shares of Cutera stock in a transaction that occurred on Monday, October 16th. The stock was sold at an average price of $39.21, for a total transaction of $156,840.00. The disclosure for this sale can be found here. Insiders sold a total of 37,968 shares of company stock worth $1,676,086 in the last ninety days. Corporate insiders own 3.30% of the company’s stock.

Several institutional investors have recently added to or reduced their stakes in the company. Parallel Advisors LLC purchased a new position in shares of Cutera in the third quarter worth approximately $117,000. Argent Capital Management LLC purchased a new position in shares of Cutera in the third quarter worth approximately $1,320,000. Cornerstone Capital Management Holdings LLC. increased its position in shares of Cutera by 76.0% in the third quarter. Cornerstone Capital Management Holdings LLC. now owns 85,700 shares of the medical device company’s stock worth $3,542,000 after acquiring an additional 37,000 shares in the last quarter. PEAK6 Investments L.P. increased its position in shares of Cutera by 533.0% in the third quarter. PEAK6 Investments L.P. now owns 64,895 shares of the medical device company’s stock worth $2,683,000 after acquiring an additional 54,643 shares in the last quarter. Finally, Mackenzie Financial Corp purchased a new position in shares of Cutera in the third quarter worth approximately $277,000. 87.64% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “Cutera (CUTR) Upgraded at Zacks Investment Research” was originally posted by The Ledger Gazette and is owned by of The Ledger Gazette. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States & international trademark and copyright legislation. The original version of this article can be viewed at https://ledgergazette.com/2018/01/12/cutera-cutr-upgraded-at-zacks-investment-research.html.

Cutera Company Profile

Cutera, Inc is a medical device company. The Company is engaged in the design, development, manufacture, marketing and servicing of laser and other energy-based aesthetics systems for practitioners across the world. The Company offers products based on product platforms, such as enlighten, excel HR, truSculpt, excel V and xeo, each of which enables physicians and other practitioners to perform aesthetic procedures for customers.

Get a free copy of the Zacks research report on Cutera (CUTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Cutera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cutera and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply